hapapapa
- Dyne Therapeutics (NASDAQ:DYN) announced Tuesday that the US Food and Drug Administration (FDA) has granted fast-track designation for DYNE-101, an experimental therapy for a rare muscle disorder called myotonic dystrophy type 1 (DM1).
- DYNE-101, a drug with orphan drug designation in